In preclinical studies, AMF-26 was demonstrated to be effective against HER2-negative, MET-positive gastrointestinal tumors that are characterized by gene amplification of MET by downregulating its membrane expression [110]. This evidence concerns the gene MET and digestive system neoplasm.